Current filters:  
Canada
Life Sciences, Biotechnology & Nanotechnology
Canada
Norton Rose Fulbright Canada LLP
The Government of Ontario has made changes to the Ontario Drug Benefit (ODB) Program in an effort to reduce the risk of drug shortages in the province during the COVID-19 outbreak.
Stikeman Elliott LLP
On March 18, 2020, the federal Minister of Health approved the Interim Order Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19.
Borden Ladner Gervais LLP
On March 16, 2020, Prime Minister Justin Trudeau announced that, among other things, Canada will temporarily restrict the entry of most travellers who are not citizens or permanent residents, ...
Gowling WLG
In the wake of the novel coronavirus (COVID-19), health professionals are exercising all efforts possible to ensure that there is no disruption in service or breakdown in patient care.
Norton Rose Fulbright Canada LLP
Health Canada is taking measures to help expedite the importation and sale of certain licensed products required to combat COVID-19. Expedited review of Health Product Submissions and Applications
Stikeman Elliott LLP
Dans la décision Kuiper v. Cook (Canada) Inc., la Cour divisionnaire de l'Ontario s'est prononcée en faveur de la certification...
Gluckstein Personal Injury Lawyers
We live in a society where we expect our public and private institutions and fellow citizens to act in a way that keeps us reasonably safe and secure. Of course, there will always be some risk of injury as we go about our business.
Bereskin & Parr LLP
A new WIPO sequence listing standard is in the works, called ST.26. It provides a modernization of the old format ST.25.
Bereskin & Parr LLP
The big news for Canadian Patent law in 2019 was the coming into force of numerous changes to the Patent Act and Patent Rules on October 30, 2019
Stikeman Elliott LLP
In Kuiper v. Cook (Canada) Inc., Ontario's Divisional Court ruled in favour of certifying a failure to warn claim in a product liability class action relating to IVC filters,...
Stikeman Elliott LLP
Dans la décision Kuiper v. Cook (Canada) Inc., la Cour divisionnaire de l'Ontario s'est prononcée en faveur de la certification d'une demande fondée...
Torys LLP
It's cold and flu season, and with it comes plenty of products promising to help you avoid this year's flu. In the U.S., the Food and Drug Agency (FDA) has been cracking down on companies claiming that
Smart & Biggar
On January 2, 2020, the Federal Court issued a decision by Justice Grammond finding certain claims of Patent No. 2,486,935 (935 Patent) invalid on the basis of anticipation,...
Smart & Biggar
On November 20, 2019, the Federal Court (FC) issued its reconsideration decision on the quantum of damages owed by Apotex for its infringement of eight Eli Lilly process...
Smart & Biggar
We reviewed 2019's top developments in Canadian life sciences IP and regulatory law in our highlights article. Below were our top 10 reads:
Smart & Biggar
In an action commenced by Allergan against Apotex in respect of ulipristal (Allergan's FIBRISTAL) under the Patent Medicines (Notice of Compliance) Regulations (PMNOC ...
Norton Rose Fulbright Canada LLP
Health Canada received an ATI request for information on Fortekor.
Fasken
The Patented Medicine Prices Review Board recently published draft Guidelines to replace the current Compendium of Policies, Guidelines and Procedures, leading up to the coming into force of the amended ...
Fasken
In preparation for the coming into force of the amended Patented Medicines Regulations, the PMPRB has published draft guidelines to replace the current Compendium of Policies, Guidelines and Procedures.
Bereskin & Parr LLP
Biotechnology companies have a long road to commercialization. Investors, shareholders and company officials often have their patience tested
FREE News Alerts
Sign Up for our free News Alerts - All the latest articles on your chosen topics condensed into a free bi-weekly email.
Popular Contributors
Upcoming Events
Tools
Font Size:
Translation
Mondaq Social Media